296 related articles for article (PubMed ID: 31035664)
1. Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer.
Xie H; Paradise BD; Ma WW; Fernandez-Zapico ME
Cells; 2019 Apr; 8(5):. PubMed ID: 31035664
[TBL] [Abstract][Full Text] [Related]
2. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Hedgehog Antagonists for Cancer Therapy.
Khatra H; Bose C; Sinha S
Curr Med Chem; 2017; 24(19):2033-2058. PubMed ID: 28302010
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications.
Grund-Gröschke S; Stockmaier G; Aberger F
Cell Commun Signal; 2019 Dec; 17(1):172. PubMed ID: 31878932
[TBL] [Abstract][Full Text] [Related]
5. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
[TBL] [Abstract][Full Text] [Related]
6. Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers.
Katoh M
Clin Sci (Lond); 2019 Apr; 133(8):953-970. PubMed ID: 31036756
[TBL] [Abstract][Full Text] [Related]
7. Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
Berardozzi S; Bernardi F; Infante P; Ingallina C; Toscano S; De Paolis E; Alfonsi R; Caimano M; Botta B; Mori M; Di Marcotullio L; Ghirga F
Eur J Med Chem; 2018 Aug; 156():554-562. PubMed ID: 30025349
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an Oxysterol Analogue with Drug-Like Properties.
Wang F; Stappenbeck F; Parhami F
Cells; 2019 May; 8(5):. PubMed ID: 31137846
[TBL] [Abstract][Full Text] [Related]
9. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
[TBL] [Abstract][Full Text] [Related]
10. Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
Rovida E; Stecca B
Semin Cancer Biol; 2015 Dec; 35():154-67. PubMed ID: 26292171
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
Carpenter RL; Ray H
Drug Saf; 2019 Feb; 42(2):263-279. PubMed ID: 30649745
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer hallmark vulnerabilities in hematologic malignancies by interfering with Hedgehog/GLI signaling.
Krenn PW; Aberger F
Blood; 2023 Dec; 142(23):1945-1959. PubMed ID: 37595276
[TBL] [Abstract][Full Text] [Related]
13. Targeting GLI Transcription Factors in Cancer.
Didiasova M; Schaefer L; Wygrecka M
Molecules; 2018 Apr; 23(5):. PubMed ID: 29695137
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
Benvenuto M; Masuelli L; De Smaele E; Fantini M; Mattera R; Cucchi D; Bonanno E; Di Stefano E; Frajese GV; Orlandi A; Screpanti I; Gulino A; Modesti A; Bei R
Oncotarget; 2016 Feb; 7(8):9250-70. PubMed ID: 26843616
[TBL] [Abstract][Full Text] [Related]
15. Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.
Arnhold V; Boos J; Lanvers-Kaminsky C
Cancer Chemother Pharmacol; 2016 Mar; 77(3):495-505. PubMed ID: 26781311
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hedgehog/Gli signaling by botanicals: a review of compounds with potential hedgehog pathway inhibitory activities.
Drenkhahn SK; Jackson GA; Slusarz A; Starkey NJ; Lubahn DB
Curr Cancer Drug Targets; 2013 Jun; 13(5):580-95. PubMed ID: 23675897
[TBL] [Abstract][Full Text] [Related]
17. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer.
Mazumdar T; DeVecchio J; Agyeman A; Shi T; Houghton JA
Oncotarget; 2011 Aug; 2(8):638-45. PubMed ID: 21860067
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.
Manetti F; Petricci E
Expert Opin Ther Pat; 2016; 26(4):529-35. PubMed ID: 26666870
[TBL] [Abstract][Full Text] [Related]
19. Strategies to target the Hedgehog signaling pathway for cancer therapy.
Xin M; Ji X; De La Cruz LK; Thareja S; Wang B
Med Res Rev; 2018 May; 38(3):870-913. PubMed ID: 29315702
[TBL] [Abstract][Full Text] [Related]
20. Arsenic: a potentially useful poison for Hedgehog-driven cancers.
Raju GP
J Clin Invest; 2011 Jan; 121(1):14-6. PubMed ID: 21183780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
